KR102311723B1 - Antimicrobial composition having synergistic antimicrobial effect - Google Patents

Abstract

Disclosed herein is an antibacterial composition having an antibacterial synergistic effect. The antimicrobial composition contains a surfactant and EDTA including at least one of a cationic surfactant and an anionic surfactant, thereby having an effect of inhibiting the activity and proliferation of bacteria even at a low concentration of the surfactant.

Description

Antibacterial composition having an antibacterial synergistic effect {ANTIMICROBIAL COMPOSITION HAVING SYNERGISTIC ANTIMICROBIAL EFFECT}

Disclosed herein is an antibacterial composition having an antibacterial synergistic effect.

Microorganisms are living things that are always around us, and there are beneficial microorganisms that help humans, but there are also harmful microorganisms that cause problems, such as causing diseases, creating odors, and giving aesthetic disgust. Therefore, in order to maintain a safe and sanitary life from microorganisms that may threaten human life, there is a need for an antimicrobial agent for sterilization and washing of microorganisms, and thus various antibacterial agents have been developed.

Specifically, anionic surfactants such as aromatic or aliphatic sulfonic acid salts or nonionic surfactants approved as food emulsifiers such as sucrose fatty acid esters and polyglycerol fatty acid esters are used as cleaning agents for tableware, cooking utensils, food processing equipment, etc. have. However, in the case of detergents based on anionic surfactants such as alkylbenzene sulfonic acid salts, they are reluctant to use due to concerns about toxicity, skin irritation, and environmental pollution due to insufficient biodegradability because they are adsorbed to food or tableware. In addition, in the case of surfactants with antibacterial activity used in a wide range of fields such as shampoos, body cleansers, pet cleaners, and antibacterial agents for textiles, they have antibacterial activity at high concentrations, dry the skin, irritate the skin and scalp, or toxin. As a disadvantage that can be added, measures to reduce its use are needed.

Korean Patent Registration No. 10-0486092

In one aspect, the present specification is for lowering the concentration of a surfactant that causes side effects and environmental pollution to the human body, and even when the surfactant is used at a low concentration, it suppresses the activity and proliferation of bacteria, thereby exhibiting an antibacterial synergistic effect. It aims to provide a composition.

In one aspect, the technology disclosed herein provides an antimicrobial composition having an antibacterial synergistic effect comprising a surfactant comprising at least one of a cationic surfactant and an anionic surfactant and ethylenediaminetetraacetic acid (EDTA).

According to an exemplary embodiment, the antibacterial composition is Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans And Aspergillus brasiliensis (Aspergillus brasiliensis) may exhibit an antibacterial effect against one or more bacteria selected from the group consisting of.

According to an exemplary embodiment, the surfactant is at least one of steartrimonium chloride, ammonium lauryl sulfate, and ammonium polyoxyethylene lauryl ether sulfate. may include.

According to an exemplary embodiment, the surfactant may be steartrimonium chloride. At this time, the antibacterial composition may exhibit an antibacterial effect against one or more of Escherichia coli and Pseudomonas aeruginosa.

According to an exemplary embodiment, the surfactant may be ammonium lauryl sulfate. In this case, the antibacterial composition may exhibit an antibacterial effect against Pseudomonas aeruginosa bacteria.

According to an exemplary embodiment, the surfactant may be ammonium polyoxyethylene lauryl ether sulfate. In this case, the antibacterial composition may exhibit an antibacterial effect against Staphylococcus aureus bacteria.

In one aspect, the technology disclosed herein uses a surfactant and EDTA including at least one of a cationic surfactant and an anionic surfactant, thereby inhibiting the activity and proliferation of bacteria even at a low concentration of the surfactant to have an antibacterial synergistic effect It has the effect of providing an antibacterial composition.

In another aspect, the technology disclosed herein provides an antibacterial composition having an antibacterial synergistic effect, thereby lowering the concentration of the surfactant used to prevent adverse effects on the human body or environmental pollution.

Hereinafter, the present invention will be described in detail.

In one aspect, the technology disclosed herein provides an antimicrobial composition having an antibacterial synergistic effect comprising a surfactant comprising at least one of a cationic surfactant and an anionic surfactant and ethylenediaminetetraacetic acid (EDTA).

According to an exemplary embodiment, the antibacterial composition is Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans And Aspergillus brasiliensis (Aspergillus brasiliensis) may exhibit an antibacterial effect against one or more bacteria selected from the group consisting of.

According to an exemplary embodiment, the surfactant includes steartrimonium chloride as a cationic surfactant, ammonium lauryl sulfate as an anionic surfactant, and ammonium polyoxyethylene lauryl ether sulfate. polyoxyethylene lauryl ether sulfate).

According to an exemplary embodiment, the EDTA is included in 0.75% by weight or less, specifically 0.7% by weight or less, based on the total weight of the antimicrobial composition, thereby having the effect of maintaining dissolution stability in the formulation. According to another embodiment, the EDTA is 0.00001 to 0.75% by weight, specifically 0.001 to 0.75% by weight, more specifically 0.01 to 0.6% by weight based on the total weight of the antimicrobial composition, so that even at a low concentration of the surfactant It has an antibacterial synergistic effect that inhibits the activity and proliferation of

According to an exemplary embodiment, the surfactant may be steartrimonium chloride. At this time, the antibacterial composition may exhibit an antibacterial effect against one or more of Escherichia coli and Pseudomonas aeruginosa. In one aspect, the steatrimonium chloride is 0.00002 to 0.001% by weight, specifically 0.00004 to 0.0001% by weight, more specifically 0.00004, based on the total weight of the antimicrobial composition in the antibacterial effect on Escherichia coli There is an effect of inhibiting the activity and proliferation of bacteria only with the use of 0.00008% by weight. In another aspect, the steatrimonium chloride is 0.01 to 0.1% by weight based on the total weight of the antibacterial composition in the antibacterial effect on Pseudomonas aeruginosa, specifically, 0.05 to 0.1% by weight only with the use of bacteria has the effect of inhibiting the activity and proliferation of

According to an exemplary embodiment, the surfactant may be ammonium lauryl sulfate. In this case, the antibacterial composition may exhibit an antibacterial effect against Pseudomonas aeruginosa bacteria. The ammonium lauryl sulfate has an effect of inhibiting the activity and proliferation of bacteria only by using 0.05 to 0.3% by weight, specifically 0.1 to 0.25% by weight, and more specifically 0.1 to 0.2% by weight based on the total weight of the antimicrobial composition.

According to an exemplary embodiment, the surfactant may be ammonium polyoxyethylene lauryl ether sulfate. In this case, the antibacterial composition may exhibit an antibacterial effect against Staphylococcus aureus bacteria. The ammonium polyoxyethylene lauryl ether sulfate is 0.00002 to 0.001% by weight, specifically 0.00004 to 0.0001% by weight, more specifically 0.00004 to 0.00008% by weight based on the total weight of the antibacterial composition. It works.

Escherichia coli is a Gram-negative bacillus, which constitutes the normal bacterial layer in the intestine and is usually non-pathogenic or pathogenic. It is originally non-pathogenic, but it is the causative agent of cholangitis, cystitis, pyelitis, and urinary tract infections.

Pseudomonas aeruginosa is a Gram-negative aerobic bacillus, although its pathogenicity to humans is weak, but because it is widely distributed in the natural environment, it causes mixed infections and secondary infections, exacerbating the disease state. In particular, when bio-resistance such as surgery or burns is low, infection can cause sepsis, and it can invade the digestive mucosa and cause diarrhea.

Staphylococcus aureus is one of the bacteria widely distributed in nature, and it is the causative bacterium that causes suppurative diseases such as suppuration of the skin, otitis media, and cystitis as well as food poisoning. are bacteria

Candida albicans is a type of fungus belonging to the imperfect fungus, which causes dermatophytosis and is the causative agent of acute and subacute candidiasis. also exist.

Aspergillus brasiliensis, also known as acid-resistant mold, has a strong organic acid production ability and is used for the production of citric acid or gluconic acid, and causes pneumonia when inhaled through the respiratory tract.

According to an exemplary embodiment, the antibacterial composition disclosed herein may be an antibacterial composition for skin, scalp, oral cavity, eye, or vagina.

According to an exemplary embodiment, the antibacterial composition disclosed herein can be used without limitation, such as a detergent, disinfectant or antibacterial agent having an effective antibacterial action. Specifically, shampoo, body cleanser, soap, foam cleanser, skin, lotion, cream, ointment, spray, toothpaste, wet tissue, kitchen cleaner, bathroom cleaner, pet cleaner, antibacterial agent for textiles, lens cleaner, etc. It can be used in antibacterial products.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not to be construed as being limited by these examples.

test example. Evaluation of minimal inhibitory concentration (MIC)

Escherichia coli (ATCC 8739); E), Pseudomonas aeruginosa (ATCC 9027); P), Staphylococcus aureus (ATCC 6538); S), Candida Albicans (Candida albicans (ATCC 10231); C) and Aspergillus brasiliensis (ATCC 16404); A) from the Microbial Resource Center (http://kctc.kribb.re.kr/kctc.aspx) Inoculated in a medium suitable for each bacteria (TSB (Tryptic Soy Broth; Difco) or SDB (Sabouraud Dextrose Broth; Difco) medium) purchased from The diluted solution was used as a test bacterial solution. However, for Candida albicans, a 1/10 diluted solution was used as the test bacterium, and for Aspergillus brasiliensis, a previously prepared spore suspension was used as the test bacterium.

In addition, steartrimonium chloride (STAC) as a cationic surfactant, ammonium lauryl sulfate (ALS) as an anionic surfactant, and ammonium polyoxyethylene lauryl ether sulfate together with EDTA in TSB or SDB medium A suspension of (ammonium polyoxyethylene lauryl ether sulfate; ALES) was used as a sample. When EDTA was used alone without a surfactant, EDTA-2NA was used, and when used together with a surfactant, the EDTA concentration was fixed at 0.05%.

Then, 200 μl of each sample was placed in row 1 of the 96-well plate, and 100 μl of the medium was added to the remaining wells. Take 100 μl of the sample from row 1, put it in row 2, mix well, then take another 100 μl and put it in row 3 for double dilution, and then add 10 μl of the bacterial solution.

After culturing at 32°C for 24 hours (however, yeast and mold cultured at 22.5°C for 72 hours), the presence or absence of proliferation of bacteria was determined to the extent of suspension, and the minimum concentration without proliferation of bacteria was determined as the MIC value. When the mixed solution was opaque and it was difficult to determine the proliferation of bacteria, it was confirmed through microscopic observation.

Test result.

The result values shown in Tables 1 to 3 above all mean concentrations, and the unit is %. For example, when looking at the synergistic effect of EDTA and STAC on E. coli, it means that when EDTA and STAC are used alone, STAC must be added to the medium at a concentration of 0.015625% to inhibit E. coli. However, when using a mixture of EDTA and STAC (EDTA is fixed at a concentration of 0.05%), it was found that E. coli was inhibited even when only 0.000049% of STAC was added to the medium. In the end, it showed a 300-fold increase in efficacy compared to when each raw material was used alone. Therefore, it can be seen that EDTA has the effect of remarkably reducing the concentration of the surfactant used.

By using the surfactant and EDTA together, it was confirmed that there was a synergistic effect showing excellent antibacterial activity when the surfactant was used at a lower concentration with EDTA than when the surfactant was used alone. Therefore, it can be seen that the antibacterial composition disclosed herein can exhibit an excellent antibacterial effect even at a concentration significantly lower than that of a conventional surfactant.

Above, specific parts of the present invention have been described in detail, and for those of ordinary skill in the art, these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. It will be obvious. Accordingly, it is intended that the substantial scope of the present invention be defined by the appended claims and their equivalents.

Claims (10)

steartrimonium chloride; and
Ethylenediaminetetraacetic acid (ethylenediaminetetraacetic acid; EDTA) containing as an active ingredient and Escherichia coli ( Escherichia coli ) and Pseudomonas aeruginosa ( Pseudomonas aeruginosa ) Antibacterial composition having an antibacterial synergistic effect on one or more bacteria.
ammonium lauryl sulfate; and
Ethylenediaminetetraacetic acid (ethylenediaminetetraacetic acid; EDTA) containing as an active ingredient and Pseudomonas aeruginosa ( Pseudomonas aeruginosa ) Antibacterial composition having an antibacterial synergistic effect on bacteria.
ammonium polyoxyethylene lauryl ether sulfate; and
Ethylenediaminetetraacetic acid (ethylenediaminetetraacetic acid; EDTA) containing as an active ingredient and Staphylococcus aureus ( Staphylococcus aureus ) Antibacterial composition having an antibacterial synergistic effect on bacteria.
4. The method according to any one of claims 1 to 3,
The EDTA is contained in an amount of 0.75% by weight or less based on the total weight of the composition, the antibacterial composition. delete delete delete delete delete delete